This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The enactment of state-specific medical cannabis access laws is associated with a decline in workers’ compensation claims, according to data published in the journal Health Economics. Authors reported that legal cannabis access was associated with a nearly seven percent decline in workers’ compensation claims.
A team of researchers affiliated with the University of Miami School of Nursing are collecting epidemiological data to better evaluate how cannabis consumers, and patients in particular, are responding to the COVID-19 pandemic. “If COVID-19 has taught us anything, it is that population-based data is vital to make informed decisions.
The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management.
There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings.
The 144-page report, compiled by the Cannabis Regulation Oversight Office (CROO), incorporates data from several state departments. This growth has allowed for the creation of new jobs, increased access to cannabis for consumers, and shows the State’s commitment to social equity in its cannabis programs.”
The self-reported use of marijuana by teenagers continues to decline nationally, according to federal data reported by the United States Substance Abuse and Mental Health Services Administration (SAMHSA). For more information, see the NORML fact-sheet , “Marijuana Regulation and Teen Use Rates.” percent to 12.5 ”
Military veterans who participate in a state’s medical marijuana access program frequently report substituting cannabis for alcohol and other controlled substances, according to data published in The American Journal of Drug and Alcohol Abuse. ”
The agency’s call for comments, initially posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
The Illinois Department of Agriculture (IDOA) and the Division of Cannabis Regulation announced today an official Metrc implementation timeline for licensed cannabis businesses transitioning from BioTrack to Metrc as Illinois’ track-and-trace data system. Metrc has additional information and support available online here.
When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf. Edited and mixed by Michael Schaeffer Omer-Man.
According to data from the Virginia Criminal Sentencing Commission, more than 15,000 people were convicted for a first or second marijuana possession offense from July 2018 to June 2019. For more information, contact Jenn Michelle Pedini , NORML Development Director & Virginia NORML Executive Director.
With everything happening in the news lately, we want to present some scientific data to help medical cannabis patients and adult-use consumers make informed decisions in regard to cannabis products available, product safety, and personal health.
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.
Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.
” Specifically, federal and state data finds that teen cannabis use has declined in past years – during the same time that many states have legalized and regulated the use of cannabis by adults. ” For more information on the public health and safety of cannabis, please see NORML’s fact-sheets here.
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
According to data from the Virginia Criminal Sentencing Commission, more than 15,000 people were convicted for a first or second marijuana possession offense from July 2018 to June 2019. For more information, contact Jenn Michelle Pedini, NORML Development Director & Virginia NORML Executive Director.
Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One. Additional information is available from the NORML fact-sheet , ‘Relationship Between Marijuana and Opioids.’
Sixty-six percent of US adults believe that “the use of marijuana should be made legal,” according to national survey data compiled by the Gallup. For more information follow Colorado NORML on Facebook , Twitter , and visit their website ! Marijuana policy should be evidence based. Dispel the myths with the NORML Fact Sheets.
Members of the United States Senate Committee on Banking, Housing, and Urban Affairs are scheduled to hear testimony next week regarding the need to provide greater access to financial services for state-licensed marijuana-related businesses. ” (Read NORML’s full testimony here.). .”
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. ” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids.
Several proposals aim to: Expand medicinal cannabis access. Data Privacy 29. What data privacy obligations do cannabis businesses have? Given the sensitive nature of medicinal cannabis information, businesses must comply with the Privacy Act 1988, including: Secure storage of patient data. simplified licensing).
Medicinal Cannabis AccessData Dashboard. To improve transparency and dataaccessibility, the TGA publishes de-identified data on the number of unapproved medicinal cannabis products accessed through the Special Access Scheme (SAS). Medicinal cannabis Special Access Scheme category B data.
This data helps Californians understand the work we have ahead of us in realizing the promises of cannabis legalization, including supporting access to a safe, legal, and equitable cannabis market across the state and combating the unregulated, illicit market”. The data tool can be found on the DCC website here: [link].
McDonell said research institutions are limited in their access to cannabis users by federal laws that could affect funding. While there are methods available for collecting that data, including a smartphone app called “Releaf,” there are still patients who are wary of sharing information, even anonymously, due to federal laws, she said.
reported a data breach stemming from a misconfigured web application that caused personal information to be accessible on the company’s website. On June 17, 2022, Silverstreak filed an official notice of the breach and sent out data breach letters to all affected parties. Console and Associates, P.C. Richard Console, Jr.
To help policymakers be more informed, a recent study out of Harvard set out to analyze the changes in cannabis use nationwide. Researchers examined data from before and after the majority of states adopted legislation legalizing at least some form of cannabis. In 2005, 61.5 In 2018, that figure was 60.9
At the same time, it has become abundantly clear that we do not have access to sufficient data and information to understand the potential scope of this issue. ” The post Ontario Ministry of Health Issues Statement Regarding Vape Illness appeared first on Puff Puff Post.
information comes available such as supplier pricing, stock changes, running costs, accounting. The ERP operates as a system, collecting data in real time and connecting it all together for your. Access Control. Since the ERP is equipped with all of the company’s information, the access to data is controlled.
As it is now prevalent in many types of software and applications, AI is revolutionizing workflows, business practices, and entire industries by changing the way businesses work, accessinformation, and analyze data. There are many ways in which AI tools are used in businesses, but most applications focus on driving growth.
Canada’s Globe & Mail reports on their court case A years-long access-to-information battle between journalists and Health Canada over data on the locations of large-scale medical cannabis growers has concluded with a Federal Court judge ruling that even city or town information could risk identifying patients and is therefore protected from (..)
Cannabis licensees, testing labs, and third-party system integrators are invited to attend a webinar on the new CCRS system that will soon replace much of the reporting currently accomplished through the Leaf Data System. The session will cover the fundamental processes and data reporting requirements of CCRS.
Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. About RYAH Group, Inc.
Barnett and Steinfeld spoke about collaboration and how DHS, CROO, and other state agencies are involved and how important it is to have access to cannabis research. It’s a huge gamechanger to have this information be available to the public,” said Delgado. For more information on News Joint Bar Service, visit here.
The TGA recently released a new medical cannabis dashboard detailing a variety of information on both SAS-A and SAS-B approvals. They announced that they’re ‘committed to ongoing transparency and will release additional datasets in the future’, such as data on Authorised Prescriber applications and the concentrations of active ingredients.
In the 144-page report, compiled by the Cannabis Regulation Oversight Office (CROO), the Department of Financial & Professional Regulation (IDFPR) states in its data summary, “Looking ahead to Fiscal Year 2025, IDFPR has already begun its efforts to further expand access to cannabis both to consumers and medical patients.
Genetic sequencing can reveal loads of important information about a cultivar including its potential to produce certain cannabinoids, terpenoids, and flavonoids. Whole Genome Data. When it comes to sequencing your cultivar’s genetics for IP purposes, the more data the better. Sequencing Methods. Comprehensive Reference Genome.
The data that is collected in Releaf App is used for multiple research studies and helps physicians identify what products patients are finding most effective. The goal of the CannaMD /Releaf partnership is to collect and leverage data-backed insights to improve the quality of healthcare for registered medical cannabis patients in Florida.
Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).
Historically, these processes have been paper-based, creating inefficiencies in data management and submission. The system also offers more transparency, giving operators easy access to the status of their applications and registrations in real-time. If any labeling or packaging information is missing, it must be uploaded immediately.
You can access the report here. Data Snapshot: Cannabis Consumer Spending and Trends: James Ahrendt , Business Intelligence Architect, Akerna. Using connected data and information to propel the cannabis industry forward, Akerna empowers businesses, governments, patients, and consumers to make smart decisions.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content